DelveInsight Business Research LLP’s Post

A new study suggests that semaglutide, widely known for diabetes and weight loss, may also reduce the risk of opioid overdoses. People with type 2 diabetes and opioid use disorder prescribed semaglutide were found to be significantly less likely to overdose compared to those on other diabetes medications. While the findings are promising, researchers like Rong Xu at Case Western Reserve University emphasize that more trials are needed to confirm this potential benefit. With over 80,000 opioid overdose deaths in the U.S. in 2023, this discovery could pave the way for new prevention strategies. https://lnkd.in/gZ6hsE6Q #Pharma #Opioid #Medicine #Healthcare #IP #VC #Patents #DeepTech

#Study results indicate that using #salt substitutes can be a viable population-wide strategy in preventing #cardiovasculardisease and controlling #hypertension. https://lnkd.in/e6QwMncE #Pharmacy #PatientCare #HeartHealt Drug Topics

EPPIC-Net ➡️ "... Only in 2018, a year when nearly 50,000 Americans died of an [opioid] overdose, did Congress start funding a program — the Early Phase Pain Investigation Clinical Network, or EPPIC-Net — designed to explore types of pain and find better solutions. 💬 Any treatments that come out of this research are unlikely to be blockbusters like opioids; by design, they will be useful to fewer people. That also makes them less appealing prospects to drug companies. So EPPIC-Net is helping small drug companies, academics, and even individual doctors design and conduct early-stage trials to test the safety and efficacy of promising pain-taming molecules. That information will be handed over to drug manufacturers for late-stage trials, all with the aim of getting new drugs approved by the FDA more quickly." https://lnkd.in/eusdb7zs

Semaglutide and similar drugs continue to demonstrate potential in various research areas. Their effects on substance abuse, including alcohol, are subjects of ongoing study. This has been observed in the patients we treat. Regarding compounded medications, while many patients use injectables, alternative options exist. The method described at subsema.com is practiced at Richie's and by pharmacies across the country. Before opting for a compounded injectable, consider a compounded sublingual (under the tongue) delivery method. Should you choose a compounded injectable (or any compound for that matter), we strongly advise inquiring about the medication's origin and requesting compound testing from the pharmacy. Stay safe and informed. #submagna #subsema #semaglutide #tirzepatide #compoundingpharmacy #independentpharmacy

Recently, Sarah Cotter attended Discovery Sessions 2024 in San Francisco to check out the latest developments in #psychedelic therapies for #CNS disorders. Here's a concise summary of the key themes from this year's meeting >> https://lnkd.in/eEfGd3FZ #CentralNervousSystem #CNSTherapies #biotech #pharmaceuticals #psychedelictherapies

The Opioid Crisis: Misuse, Mismanagement, or Misunderstanding? The opioid crisis is a tangled web of statistics and assumptions, where numbers are often granted undue certainty, and pain is quantified through imperfect means. A recent study in Addiction explores the complexities of opioid prescribing for chronic non-cancer pain (CNCP) and the problematic use of pharmaceuticals, unearthing biases and inconsistencies in definitions and diagnoses. The perceived prevalence of opioid misuse in pain management is as varied as it is misunderstood, raising questions about the reliability of data and the motivations behind its interpretation. https://lnkd.in/ecRiZBHy

Patients using a #predictivealarm saw a reduction of more than 40% in time spent below range in #hypoglycemia and more than 60% in time spent in severe hypoglycemia. https://lnkd.in/eiU6KTGY #Pharmacy #CGM #RealTimeCGM #DiabetesTreatment #DiabetesAwarenes Drug Topics

💊 𝗨.𝗦. 𝗙𝗗𝗔 approves Bristol Myers Squibb’s Schizophrenia drug (Xanomeline–Trospium, 𝗖𝗢𝗕𝗘𝗡𝗙𝗬™), the first new drug for schizophrenia in more than 30 years. ☑ COBENFY represents the first new pharmacological approach to treat schizophrenia in decades, with a mechanism of action distinct from current therapies. 🌟 ☑ First-in-class Muscarinic Agonist "𝗗𝘂𝗮𝗹 𝗮𝗴𝗼𝗻𝗶𝘀𝘁" for treating schizophrenia in adults. Xanomeline selectively activates M1 and M4 muscarinic receptors while avoiding D2 receptor pathway to reduce movement-related side effects. ☑ While Trospium, a muscarinic antagonist, blocks receptors in peripheral tissues thereby reducing peripheral side effects like nausea and urinary retention caused by Xanomeline. Synergism- this is interesting! ✔ 📊 Approval decision was supported by data from the 𝗘𝗠𝗘𝗥𝗚𝗘𝗡𝗧 clinical trials showing statistically significant reductions of schizophrenia symptoms. 👩⚕️ The safety and tolerability profile of COBENFY has been established across acute and long-term trials in schizophrenia. 👇 For more details: https://lnkd.in/dRTnKsei #fda #drug #medicine #health #mentalhealth #healthcare #schizophrenia #pharmaceutical #Innovation

Post-Traumatic Stress Disorder Treatment: Institute for Clinical and Economic Review (ICER) Criticizes Lykos Therapeutics’ Therapy for Trial Design Issues The Institute for Clinical and Economic Review (ICER) has criticized the clinical trials of Lykos Therapeutics' MDMA-assisted psychotherapy for PTSD, citing issues like functional unblinding and flawed trial design, which hinder a reliable assessment of the therapy’s benefits and harms. Lykos Therapeutics’ therapy combines MDMA, a controlled psychoactive substance, with psychotherapy to help PTSD patients process traumatic experiences. Despite promising results, the therapy faces controversy due to MDMA's recreational use and Schedule 1 classification. With the FDA set to review the therapy soon, Institute for Clinical and Economic Review (ICER)’s report underscores the need for rigorous evaluation, while Lykos Therapeutics argues that Institute for Clinical and Economic Review (ICER) overlooked patient perspectives and FDA feedback. The outcome of the FDA review and Institute for Clinical and Economic Review (ICER)'s upcoming public meeting will be crucial in determining the future of this novel PTSD treatment. For more details please click the link! https://lnkd.in/dQ6v9hK5 #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

Innovation in pharmaceutical treatments is primarily driven by commercial interests, resulting in fewer medicines being developed in economically less attractive fields. When society faces significant health challenges, we recognize the need to incentivize and reward innovation, particularly in areas that are not commercially appealing to companies. Examples include pediatric illnesses, rare diseases, or antimicrobial resistance. The EU is currently revising its pharmaceutical legislation, the first revision in 20 years. This presents a significant opportunity to focus on mental health innovation and realign our healthcare innovation priorities to more effectively address the unmet needs in mental health care. For further insights, read my recent article “Closing the innovation gap: Advancing psychedelic therapy and medicines in EU mental health care,” published in Open Access Government. https://lnkd.in/dW9iaW9M